Citrate/heparin/taurolidine

Drug Profile

Citrate/heparin/taurolidine

Alternative Names: Citrate/taurolidine/heparin; CRMD 003; CRMD 004; Heparin/citrate/taurolidine; Heparin/taurolidine/citrate; Neutrolin; Taurolidine/citrate/heparin; Taurolidine/heparin/citrate

Latest Information Update: 25 Jul 2016

Price : $50

At a glance

  • Originator ND Partners
  • Developer CorMedix
  • Class Alkanesulfonic-acids; Antibacterials; Anticoagulants; Citrates; Heparins; Small molecules; Thiadiazines
  • Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease 1 stimulants; Factor Xa inhibitors; Heparanase inhibitors; Lipopolysaccharide inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Catheter infections

Highest Development Phases

  • Marketed Catheter infections

Most Recent Events

  • 18 Jul 2016 Launched for Catheter infections (Prevention) in Middle East (unspecified route)
  • 11 May 2016 CorMedix plans a phase III LOCK-IT 200 trial
  • 11 May 2016 Registered for Catheter infections (Prevention) in Middle East (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top